Lexicon Pharmaceuticals Inc
Suletud
SektorTervishoid
2 -6.98
Ülevaade
Aktsiahinna muutus
24h
Min
2
Max
2.13
Sissetulek | -32M -33M |
|---|---|
Müük | -20M 692K |
Aktsiakasum | -0.06 |
Kasumimarginaal | -4,742.486 |
Töötajad | 81 |
EBITDA | -30M -29M |
Järgmine tulemuste avaldamine | 5. nov 2026 |
|---|
Turukapital | -38M 997M |
|---|---|
Eelmine avamishind | 8.98 |
Eelmine sulgemishind | 2 |
Uudiste sentiment
By Acuity
67%
33%
304 / 339 Pingereas Healthcare
Lexicon Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Lexicon Pharmaceuticals Inc Prognoos
Sentiment
By Acuity
304 / 339 Pingereas Tervishoid
Uudiste sentiment
Tõusu märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Üle keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.